Citadel Advisors LLC grew its stake in Aclaris Therapeutics Inc (NASDAQ:ACRS) by 620.6% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 242,016 shares of the biotechnology company’s stock after purchasing an additional 208,429 shares during the quarter. Citadel Advisors LLC owned approximately 0.79% of Aclaris Therapeutics worth $6,247,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of ACRS. Schwab Charles Investment Management Inc. lifted its holdings in Aclaris Therapeutics by 40.5% during the second quarter. Schwab Charles Investment Management Inc. now owns 61,765 shares of the biotechnology company’s stock worth $1,676,000 after acquiring an additional 17,804 shares during the period. Franklin Resources Inc. lifted its holdings in Aclaris Therapeutics by 55.4% during the second quarter. Franklin Resources Inc. now owns 1,955,381 shares of the biotechnology company’s stock worth $53,030,000 after acquiring an additional 697,104 shares during the period. Rosenblum Silverman Sutton S F Inc. CA lifted its holdings in Aclaris Therapeutics by 17.3% during the second quarter. Rosenblum Silverman Sutton S F Inc. CA now owns 38,400 shares of the biotechnology company’s stock worth $1,041,000 after acquiring an additional 5,650 shares during the period. Nationwide Fund Advisors lifted its holdings in Aclaris Therapeutics by 72.4% during the second quarter. Nationwide Fund Advisors now owns 11,423 shares of the biotechnology company’s stock worth $310,000 after acquiring an additional 4,796 shares during the period. Finally, New York State Common Retirement Fund lifted its holdings in Aclaris Therapeutics by 85.1% during the second quarter. New York State Common Retirement Fund now owns 23,661 shares of the biotechnology company’s stock worth $642,000 after acquiring an additional 10,877 shares during the period. Institutional investors own 92.10% of the company’s stock.

Shares of Aclaris Therapeutics Inc (ACRS) opened at $23.22 on Thursday. Aclaris Therapeutics Inc has a 52-week low of $21.47 and a 52-week high of $33.25.

Aclaris Therapeutics (NASDAQ:ACRS) last released its earnings results on Tuesday, November 7th. The biotechnology company reported ($0.63) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.86) by $0.23. The firm had revenue of $0.68 million during the quarter, compared to analysts’ expectations of $2.00 million. equities research analysts predict that Aclaris Therapeutics Inc will post -2.59 EPS for the current fiscal year.

ACRS has been the topic of a number of recent analyst reports. Cantor Fitzgerald reiterated a “buy” rating and set a $50.00 price target on shares of Aclaris Therapeutics in a report on Tuesday, November 7th. Zacks Investment Research upgraded Aclaris Therapeutics from a “hold” rating to a “buy” rating and set a $31.00 price target on the stock in a report on Tuesday, October 10th. ValuEngine lowered Aclaris Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, September 12th. JMP Securities reiterated an “outperform” rating and set a $39.00 price target on shares of Aclaris Therapeutics in a report on Friday, September 8th. Finally, BidaskClub lowered Aclaris Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, August 9th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $39.20.

TRADEMARK VIOLATION NOTICE: This piece was posted by Daily Political and is owned by of Daily Political. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of international trademark and copyright law. The correct version of this piece can be accessed at https://www.dailypolitical.com/2017/11/30/citadel-advisors-llc-buys-208429-shares-of-aclaris-therapeutics-inc-acrs.html.

Aclaris Therapeutics Profile

Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.

Want to see what other hedge funds are holding ACRS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aclaris Therapeutics Inc (NASDAQ:ACRS).

Institutional Ownership by Quarter for Aclaris Therapeutics (NASDAQ:ACRS)

Receive News & Ratings for Aclaris Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.